Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study

Prior treatment

• Have participated in an investigational drug or device study within 30 days of the baseline visit
• Have had previous neurosurgery for Huntington's disease or other movement disorders.
• Have a history of substance abuse (based on DSMIV criteria) within the past 12 months prior to screening.
• Are not weight stable for at least three months prior to enrolling in the study, defined as greater than 2 kg change in body mass.

Other illness

• Have clinically significant cognitive impairment that hinders the ability to appropriately consent or adhere to detailed study directions, in the opinion of the principal investigator.
• Have clinically relevant hematologic, hepatic, cardiac, thyroid, or renal disease.

Lab values

• Have a clinically significant medical, surgical, laboratory, or behavioral abnormality which in the judgment of the site Investigator makes the subject unsuitable for the study.

Other

• Subjects ineligible to participate in this study are persons who:
• Have a presence of clinically significant psychosis and/or confusional states, in the opinion of the principal investigator.
• If female, are pregnant or breastfeeding.
• Have a high-risk for nutritional deficiency.
• Express a desire to lose weight during the study.
• Have consistently practiced a time-restricted eating protocol within 3 months of trial onset.

• Subjects eligible to participate in this study are persons who:
• Are of at least 21 years of age at Screening.
• Must fulfill one of the following criteria:
  • Premanifest late prodromal HD as defined by a genetically confirmed CAG repeat greater than or equal to 36 and a CAG-Age Product (CAP) score greater than 368 (CAP = (Age) x (CAG - 33.66)).
  • Early manifest (stage I and II) HD as defined by a TFC greater than or equal to 7. Subjects must have been determined to have a clinical diagnosis of HD by the site investigator as defined by a diagnostic confidence level (DCL) of 4.
• Must fulfill both of the following criteria:
  • Have undergone genetic testing with a known CAG repeat greater than or equal to 36.
  • No features of juvenile HD (Westphal variant)
  • Clarification of CAG Repeat Number (Allele length) Testing Requirements:
  • A CAG repeat number obtained prior to the Screening Visit will be used to document subject eligibility if at Screening there is documentation available in the subject's record that states that the subject has an expanded CAG repeat (greater than or equal to 36) from a prior validated laboratory assessment.
• All female subjects of childbearing potential must have a negative urine pregnancy test at baseline, and female subjects of childbearing potential must practice a highly effective method of contraception (e.g., oral contraceptives, a barrier method of birth control \[e.g. condoms with contraceptive foams, diaphragms with contraceptive jelly\], intrauterine devices, partner with vasectomy or sexual abstinence) for the duration of the study.
• Are willing and capable of providing informed consent for study participation.
• Are capable of reading, writing, and communicating effectively with others.